AbbVie 2012 Annual Report Download - page 99

Download and view the complete annual report

Please find page 99 of the 2012 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 200

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200

Note 14 Segment and Geographic Area Information
AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie’s U.S.
sales are to three wholesalers. Outside the United States, products are sold primarily to health care
providers or through distributors, depending on the market served. Net sales of key products were as
follows.
years ended December 31 (in millions) 2012 2011 2010
HUMIRA $ 9,265 $ 7,932 $ 6,508
AndroGel 1,152 874 649
TriCor/TRILIPIX 1,098 1,372 1,355
Kaletra 1,013 1,170 1,223
Niaspan 911 976 927
Synagis 842 792 726
Lupron 800 810 741
Sevoflurane 602 665 664
Synthroid 551 522 451
Norvir 389 419 344
Zemplar 383 409 596
Creon 353 332 246
All other 1,021 1,171 1,208
Net sales $18,380 $17,444 $15,638
Net sales to external customers, based on the country that sold the product, were as follows.
years ended December 31 (in millions) 2012 2011 2010
United States $10,435 $ 9,712 $ 8,971
The Netherlands 776 904 845
Germany 756 701 635
Japan 718 616 484
United Kingdom 552 496 418
Spain 525 569 515
France 500 516 479
Canada 500 446 374
Brazil 434 382 287
Italy 408 428 385
All other countries 2,776 2,674 2,245
Net sales $18,380 $17,444 $15,638
Long-lived assets, consisting of net property and equipment in the United States and Puerto Rico,
totaled approximately $1.6 billion and $1.5 billion as of December 31, 2012 and 2011, respectively.
93